Wegovy Developer announces the pill for obesity which decreases by weight of 16%

Wegovy Developer announces the pill for obesity which decreases by weight of 16%


According to a study issued by the pharmacist, patients also showed improvements in daily physical activities


Summary

Novo Nordisk Pharmaceuticals has presented an oral version of traffic lights that reduces 16.6% of the weight in people with obesity, with results comparable to Wegovy injectable and further physical benefits.




The version of Tablet of semaglutado can cause weight loss of 16.6% in people with obesity. This is what a study published on Thursday 17 from the scientific newspaper The New England Journal of Medicine.

The research, conducted by the new Danish pharmacist Nordisk and called “Oasis 4”, analyzed 307 obese or overweight adults, with one or more comorbilities and without diabetes for 64 weeks. All the volunteers were medicated with the oral 25 mg version of the formulation which is the same as wegovy, also known as “slimming pen”.

According to data, patients had an average of 16.6% in weight loss during the study period, compared to 2.7% of those who receive placebo. Almost a third of the volunteers even reduced 20% or more weight, with side effects similar to those of the injectable formulation. The results are compatible with Wegovy injectable.

In addition to weight loss, volunteers also showed improvements in the ability to carry out daily physical activities and cardiovascular risk factors. However, there was an incidence of 6.9% of side effects such as nausea (46.6% against 18.6% for placebo) and vomiting (30.9% against 5.9% for placebo).

The semaglutido is waiting for the evaluation of the food and drug Administration (FDA), the body responsible for the safety and effectiveness of food, medicines, organic products and medical devices in the United States. If approved, it will be the first oral oral treatment of the country.

Source: Terra

You may also like